Summary
Global Markets Direct’s, ‘Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H1 2016’, provides in depth analysis on Calcitonin Gene Related Peptide (CGRP) targeted pipeline therapeutics.
The report provides comprehensive information on the Calcitonin Gene Related Peptide (CGRP), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics development and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Calcitonin Gene Related Peptide (CGRP)
- The report reviews Calcitonin Gene Related Peptide (CGRP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics and enlists all their major and minor projects
- The report assesses Calcitonin Gene Related Peptide (CGRP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Calcitonin Gene Related Peptide (CGRP) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Calcitonin Gene Related Peptide (CGRP)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Calcitonin Gene Related Peptide (CGRP) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
Alder Biopharmaceuticals Inc.
BCN Peptides, S.A.
Boehringer Ingelheim GmbH
Eli Lilly and Company
BCN Peptides, S.A.
Teva Pharmaceutical Industries Ltd.
Noxxon Pharma AG
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Calcitonin Gene Related Peptide (CGRP) Overview 6
Therapeutics Development 7
Calcitonin Gene Related Peptide (CGRP) - Products under Development by Stage of Development 7
Calcitonin Gene Related Peptide (CGRP) - Products under Development by Therapy Area 8
Calcitonin Gene Related Peptide (CGRP) - Products under Development by Indication 9
Calcitonin Gene Related Peptide (CGRP) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Calcitonin Gene Related Peptide (CGRP) - Products under Development by Companies 12
Calcitonin Gene Related Peptide (CGRP) - Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Mechanism of Action 15
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Calcitonin Gene Related Peptide (CGRP) - Companies Involved in Therapeutics Development 21
Alder Biopharmaceuticals Inc. 21
BCN Peptides, S.A. 22
Boehringer Ingelheim GmbH 23
Eli Lilly and Company 24
BCN Peptides, S.A. 25
Teva Pharmaceutical Industries Ltd. 26
Noxxon Pharma AG 27
Calcitonin Gene Related Peptide (CGRP) - Drug Profiles 28
ALD-403 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
DD-04107 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
galcanezumab - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
NOXL-41 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
olcegepant - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
TEV-48125 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Calcitonin Gene Related Peptide (CGRP) - Dormant Projects 41
Calcitonin Gene Related Peptide (CGRP) - Discontinued Products 43
Calcitonin Gene Related Peptide (CGRP) - Featured News & Press Releases 44
Apr 12, 2016: Teva to Present Data on TEV-48125 at 68th AAN Annual Meeting 44
Mar 28, 2016: Alder Reports Phase 2b Trial of ALD403 Meets Primary and Secondary Endpoints Demonstrating Migraine Prevention in Patients with Chronic Migraine 44
Feb 09, 2016: Alder BioPharmaceuticals Strengthens and Expands Leadership Team Supporting Advancement of ALD403 Toward Future Commercialization 46
Oct 13, 2015: Alder BioPharmaceuticals Initiates Pivotal Clinical Trial of ALD403 for Preventative Treatment of Frequent Episodic Migraine 47
Sep 30, 2015: Important New Data from Teva's TEV-48125 Phase 2B Migraine Program Published in Lancet Neurology in Back-to-Back Articles 48
Jun 18, 2015: Teva to Present New Findings at the American Headache Society Meeting - Analysis of Migraine Phase IIb Studies Provides Novel Insights into TEV-48125 Efficacy and Safety in Both Episodic & Chronic Migraine 49
Jun 17, 2015: Lilly's investigational medicine for prevention of migraine met primary endpoint in a Phase 2b study 51
May 15, 2015: Alder Presents Positive Clinical Data for ALD403 at the 17th Congress of the International Headache Society 52
May 14, 2015: Teva Presents Further Data from Phase IIb with TEV-48125 in Chronic Migraine at the International Headache Society Congress (IHC): Efficacy and Safety Results at All Doses and Endpoints Present Robust Case for Progression to Phase III 53
May 06, 2015: Alder Announces Presentations at 17th Congress of the International Headache Society on Data from ALD403 Clinical Trials 54
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 56
Disclaimer 57
List of Tables
Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Indication, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Products under Development by Companies, H1 2016 13
Assessment by Monotherapy/Combination Products, H1 2016 14
Number of Products by Stage and Mechanism of Action, H1 2016 16
Number of Products by Stage and Route of Administration, H1 2016 18
Number of Products by Stage and Molecule Type, H1 2016 20
Pipeline by Alder Biopharmaceuticals Inc., H1 2016 21
Pipeline by BCN Peptides, S.A., H1 2016 22
Pipeline by Boehringer Ingelheim GmbH, H1 2016 23
Pipeline by Eli Lilly and Company, H1 2016 24
Pipeline by BCN Peptides, S.A., H1 2016 25
Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016 26
Pipeline by Noxxon Pharma AG, H1 2016 27
Dormant Projects, H1 2016 41
Dormant Projects (Contd..1), H1 2016 42
Discontinued Products, H1 2016 43
List of Figures
Number of Products under Development for, H1 2016 7
Number of Products under Development by Top 10 Indication, H1 2016 9
Comparative Analysis by Early Stage Products, H1 2016 11
Assessment by Monotherapy/Combination Products, H1 2016 14
Number of Products by Mechanism of Actions, H1 2016 15
Number of Products by Stage and Mechanism of Actions, H1 2016 15
Number of Products by Routes of Administration, H1 2016 17
Number of Products by Stage and Routes of Administration, H1 2016 17
Number of Products by Molecule Types, H1 2016 19
Number of Products by Stage and Molecule Type, H1 2016 19
